The deal also gives Novartis exclusive options to license additional next-generation programs built on Abogen's proprietary ...

In US regulatory news, the FDA opened applications for its Expedited IND Pilot on September 15. 1 The program pairs drug ...

In June 1937, a salesman for the S. E. Massengill Company reported demand in the southern states for sulfanilamide in liquid ...

Manufacturers are encouraged to treat resiliency policy as an actionable trend and proactively shape solutions rather than ...

Scarboro contends these findings should be treated as design information rather than as a sign that patients need more ...

Companies showcasing equipment and services at the event include Shilpa Biologicals (Booth 12J33), which is announcing the ...

Access Part 1 of this interview, in which Piervincenzi explains how benchmarking could reward reliable generic drug suppliers ...

Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation. Michael Levy, senior vice president, ...

Machine-readable digital standards integrated into LIMS, ELNs, and regulatory platforms reduce transcription risk, streamline ...

The FDA has approved AbbVie's JUVMO (tavapadon), as the first and only selective D1/D5 receptor agonist for adults with ...

In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol ...

Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions ...